License includes 50/50 profit share and additional payments of up to $185 million dependent on achieving clinical development and sales milestones, and subject to certain reductions Phase 3 clinical trial results for CPP-1X/sul in patients with Familial Adenomatous Polyposis expected in 1H 2019 TUCSON, Arizona, Aug. 13, 2018 – Cancer Prevention Pharmaceuticals, Inc. (CPP), a … Continue reading Cancer Prevention Pharmaceuticals Completes North American Licensing Deal with Mallinckrodt